<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816997</url>
  </required_header>
  <id_info>
    <org_study_id>VGHIRB 2011-10-005IA</org_study_id>
    <nct_id>NCT01816997</nct_id>
  </id_info>
  <brief_title>The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose</brief_title>
  <official_title>The Influence of Statins on Glucose Homeostasis and the Biomarkers of Diabetes in Subjects With Impaired Fasting Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effects of rosuvastatin (maybe the highest diabetogenic) and pravastatin (seems
      to be protective) on the glucose homeostasis and other biomarkers in subjects with impaired
      fasting glucose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statin therapy effectively reduces cardiovascular events. However, trial data1 and
      meta-analyses suggest that statins also confer increased risk of development of diabetes. In
      order to elucidate whether statins increase risk of diabetes, investigators conducted this
      study to evaluate the effects of rosuvastatin (maybe the highest diabetogenic) and
      pravastatin (seems to be protective) on the glucose homeostasis and other biomarkers in
      subjects with impaired fasting glucose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the glucose homeostasis and some biomarkers of diabetes among control, parvastatin and rosuvastatin groups.
Glucose and insulin response during OGTT. Some markers of insulin resistance and insulin secretion calculated from OGTT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Some biomarkers of diabetes</measure>
    <time_frame>6 months</time_frame>
    <description>Such as GLP-1, GIP, IGF-1, HbA1c, FPG etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of glucose homeostasis</measure>
    <time_frame>5 to 10 years.</time_frame>
    <description>We will repeat FPG and A1C every 6 months and OGTT every 1-2 years for up to 10 years to investigate the change of these parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic complications of diabetes</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Retinopathy: The change of steps on the ETDRS Severity Scales. Nephropathy: UACR and eGFR change. All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of diabetes</measure>
    <time_frame>5 to 10 years.</time_frame>
    <description>We will repeat FPG and A1C every 6 months and OGTT every 1-2 years for up to 10 years to investigate the incidence of diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic complications of diabetes</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Diabetic retinopathy: Development of advanced diabetic retinopathy. Advanced diabetic retinopathy was defined as development of proliferative diabetic retinopathy, retinopathy treated with laser photocoagulation or vitrectomy.
Nephropathy: Development of macroalbuminuria (UACR &gt;30 mg/mmol creatinine), a severe decline in eGFR (&lt;30 mL/[minâ€¢1.73 m2]).
Cardiovacular events: angina, myocardial infarction, heart failure, acute coronary syndrome and cerebrovascular accident.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <other_name>Pravastatin (Mevalotin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>placebo</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 35-70 years old

          2. Fasting blood glucose 100-125 mg/dL

        Exclusion Criteria:

          1. A1C &gt;7.0%

          2. 2hr glucose during OGTT &gt;200 mg/dL

          3. Total cholesterol &gt;280 mg/dL

          4. Previous diabetic history, coronary artery disease

          5. Allergy to rosuvastatin or parvastatin

          6. Baseline ALT more than 3 times UNL

          7. Serum Cr &gt; 2.0 mg/dL

          8. Pregnancy, breast feeding or plan to be pregnant woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harn-Shen Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harn-Shen Chen, MD, PhD</last_name>
    <phone>886-2-28757515</phone>
    <email>chenhs@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harn-Shen Chen, MD, PhD</last_name>
      <phone>886-2-28757515</phone>
    </contact>
    <investigator>
      <last_name>Harn-Shen Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>November 15, 2013</last_update_submitted>
  <last_update_submitted_qc>November 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>Taipei Veterans General Hospital</investigator_title>
  </responsible_party>
  <keyword>Statins</keyword>
  <keyword>Glucose homeostasis</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Impaired fasting glucose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

